A blister pack containing Femoden oral contraceptive tablets, produced by Bayer AG, sits on a pharmacy counter in this arranged photograph in London, U.K., on Thursday, Dec. 29, 2016. The rapid pace of innovation among drugmakers may continue to be overshadowed by broader investment themes, such as the switch away from defensive stocks into more cyclical industries, during 2017, according to Bloomberg Intelligence. Chris Ratcliffe—Bloomberg/Getty Images
- Previous Rank165
- Revenues ($M)52569
- Revenue Percent Change0.3
- Profits ($M)5010.6
- Profits Percent Change9.9
- Assets ($M)86731
- Employees115170
Company Information
CEO | Werner Baumann |
Sector | Health Care |
Industry | Pharmaceuticals |
HQ Location | Leverkusen, Germany |
Website | www.bayer.com |
Years on Global 500 List | 23 |
Employees | 115,170 |
Key Financials (Last Fiscal Year)
Revenues ($M) | $52,569 |
Profits ($M) | $5,010.6 |
Assets ($M) | $86,731 |
Total Stockholder Equity ($M) | $31,990 |
Profit Ratios
Profit as % of Revenues | 9.5% |
Profits as % of Assets | 5.8% |
Profits as % of Stockholder Equity | 15.7% |